Skip to main content
NIH funding notice RFA-HD-22-003

Contraceptive Development Research Centers Program (P50 Clinical Trial Optional)

Closed on November 29, 2021.

Posted
November 19, 2020
Close date
November 29, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,715,448 in first-year total cost, median $1,715,448.

Most frequent study sections

  1. Special Emphasis Panel[ZHD1 DSR-Y (55)]1

Most frequent institutions

  1. BOSTON UNIVERSITY MEDICAL CAMPUS1
Competing awards under RFA-HD-22-003 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022Antibody-based Contraceptive MPTs: Advancing the Human Contraceptive Antibody (HCA) through Clinical Trials2P50HD096957-05ANDERSON, DEBORAH JWHALEY, KEVINBOSTON UNIVERSITY MEDICAL CAMPUS, MA$1,715,448ZHD1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-HD-22-003: Contraceptive Development Research Centers Program (P50 Clinical Trial Optional) | ScienceDex | ConductScience